Article
DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Cell communication and signaling : CCS - 27 Oct 2022
Chu Xuan, Zhong Liang, Dan Wenran, Wang Xiao, Zhang Zhonghui, Liu Zhenyan, Lu Yang, Shao Xin, Zhou Ziwei, Chen Shuyu, Liu Beizhong
Abstract excerpt
BACKGROUND: DNA methyltransferase 3A (DNMT3A) often mutate on arginine 882 (DNMT3AR882) in acute myeloid leukemia (AML). AML patients with DNMT3A R882 mutation are usually resistant to daunorubicin treatment; however, the associated mechanism is still unclear. Therefore, it is urgent to investigate daunorubicin resistance in AML patients with DNMT3A R882 mutant. METHOD: AML cell lines with DNMT3A-wild type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.